InnFocus releases clinical results on MicroShunt implant
InnFocus, Inc. recently reported on a series of 43 glaucoma patients (n=34, 22, and 17 at one, two, and three years, respectively) treated with its MicroShunt implant.
Nice, France-InnFocus, Inc. recently reported on a series of 43 glaucoma patients (n=34, 22, and 17 at one, two, and three years, respectively) treated with its MicroShunt implant.
According to the company, the average intraocular pressure (IOP) reduction from medicated baseline (23.6 mmHg) was 50 percent, averaging 10-12 mmHg over three years.
The company also released data showing 85 percent of patients are totally off glaucoma medication with a reduction in medication from 2.8 to 0.4 meds/patient at three years. The patients showed no long-term adverse events. None needed to be converted to trabeculectomy or large plate valves.
InnFocus has initiated Phase I Food and Drug Administration trials at 10 centers in the U.S.
The InnFocus MicroShunt provides a method of shunting aqueous humor from the anterior chamber to a diffuse bleb without the use of a scleral flap, using a micro-tube to control flow made from the SIBS material.
